EGFR and non-small cell lung carcinoma: Recent studies have revealed an increase in the overall survival (OS) rates of individuals with advanced NSCLC who fulfill the criteria for immunotherapy, including programmed cell death 1 (PD‐1) and programmed cell death ligand‐1 (PD‐L1), or targeted therapy using epidermal growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs).